CN118871096A - 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物 - Google Patents

包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物 Download PDF

Info

Publication number
CN118871096A
CN118871096A CN202380022428.3A CN202380022428A CN118871096A CN 118871096 A CN118871096 A CN 118871096A CN 202380022428 A CN202380022428 A CN 202380022428A CN 118871096 A CN118871096 A CN 118871096A
Authority
CN
China
Prior art keywords
tryptophan
hydroxytryptophan
pharmaceutical composition
peripheral degradation
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380022428.3A
Other languages
English (en)
Chinese (zh)
Inventor
约阿希姆·坎普拉德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN118871096A publication Critical patent/CN118871096A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
CN202380022428.3A 2022-02-16 2023-02-08 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物 Pending CN118871096A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102022103658.8 2022-02-16
DE102022103658.8A DE102022103658A1 (de) 2022-02-16 2022-02-16 Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer
PCT/EP2023/053129 WO2023156275A1 (en) 2022-02-16 2023-02-08 Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor

Publications (1)

Publication Number Publication Date
CN118871096A true CN118871096A (zh) 2024-10-29

Family

ID=85221827

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380022428.3A Pending CN118871096A (zh) 2022-02-16 2023-02-08 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物

Country Status (10)

Country Link
US (1) US20250161270A1 (cg-RX-API-DMAC10.html)
EP (1) EP4479027A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025505294A (cg-RX-API-DMAC10.html)
KR (1) KR20240152875A (cg-RX-API-DMAC10.html)
CN (1) CN118871096A (cg-RX-API-DMAC10.html)
AU (1) AU2023222362A1 (cg-RX-API-DMAC10.html)
CA (1) CA3243635A1 (cg-RX-API-DMAC10.html)
DE (1) DE102022103658A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024009966A (cg-RX-API-DMAC10.html)
WO (1) WO2023156275A1 (cg-RX-API-DMAC10.html)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126672A (en) 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
CH652025A5 (de) 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
DE3642668A1 (de) 1986-12-13 1988-06-23 Kamprad Joachim Schmerzmittel fuer menschen
FR2654931B1 (fr) 1989-11-24 1993-08-27 Trouillas Paul Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa.
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
EP1751312A4 (en) * 2004-05-21 2010-01-27 Univ Duke POLYMORPHISM IN TRYPTOPHAN HYDROXYLASE 2 REGULATING BRAIN SEROTONIN SYNTHESIS
DE102004039196B4 (de) 2004-08-12 2008-07-31 Dr.Kamprad Kg Neue Formulierung für L-Tryptophan
US20060257469A1 (en) * 2005-04-05 2006-11-16 Bulka Yochanan R Enhanced indoleamine and catecholamine bio-availability via catechin inhibition of L-Dopa decarboxylase
ES2948788T3 (es) * 2018-01-29 2023-09-19 Univ Duke Composiciones y métodos para mejorar la biodisponibilidad del 5-hidroxitriptófano

Also Published As

Publication number Publication date
JP2025505294A (ja) 2025-02-21
WO2023156275A1 (en) 2023-08-24
CA3243635A1 (en) 2023-08-24
DE102022103658A1 (de) 2023-08-17
EP4479027A1 (en) 2024-12-25
AU2023222362A1 (en) 2024-09-12
KR20240152875A (ko) 2024-10-22
US20250161270A1 (en) 2025-05-22
MX2024009966A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
KR102795284B1 (ko) 베타-히드록시부티레이트 및 부탄디올의 s-거울상이성질체 및 이의 사용 방법
JP2001513487A (ja) 糖尿病治療用組成物及び治療方法
AU2004285436B2 (en) Composition and dosage form for sustained effect of levodopa
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
ZA200700395B (en) Novel formulation for L-tryptophane comprising carbidopa/benserazide
US6017946A (en) Serotonin containing formulation for oral administration and method of use
US8053472B2 (en) Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
JP2002512191A (ja) Ｌ−カルニチンまたはアルカノイルｌ−カルニチンおよびｎａｄｈおよび／またはｈａｄｐｈを含む組成物。
US20110117070A1 (en) Compositions and methods for treating headache
EP4479027A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
CN114557992B (zh) 一种复方药物组合物在制备治疗间质性肺炎药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination